ShouTi's platform combines the latest advancements in computational chemistry, visualization of molecular interactions, and data integration to design orally available, superior medicines that overcome current limitations of biologic and peptide drugs.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/20/21 | $100,000,000 | Series B |
BVF Partners Casdin Capital Cormorant Asset Management Janus Henderson Investors Lilly Asia Ventures Monashee Capital Sage Partners Stork Capital Surveyor Capital TCG Terra Magnum Capital Partners Woodline Partners | undisclosed |
